Overview

Safety, Tolerability and PK Evaluation of BZ371A, Topically Administered

Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate pharmacokinetics, safety and tolerability profile of BZ371A topically administered in healthy patients.
Phase:
Phase 1
Details
Lead Sponsor:
Biozeus Biopharmaceutical S.A.
Collaborator:
Azidus Brasil Scientific Research and Development Ltda